Tauopathy
MONDO:0005574Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (tau proteins) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with alzheimer disease; dementia; parkinsonian disorders; progressive supranuclear palsy (supranuclear palsy, progressive); and corticobasal degeneration.
1193 clinical trials for this condition and its sub-types, 24 tagged with Tauopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Tauopathy
-
Alzheimer disease 1,187 trials
5 sub-types
- Familial Alzheimer disease 13 trials · 55 incl. sub-types Sub-types →
- Alzheimer disease 16 1 trial
- Alzheimer disease 17 1 trial
- Alzheimer disease 18 1 trial
- Alzheimer disease 19 1 trial
-
Argyrophilic grain disease 0 trials
Most studied deeper sub-types
-
Experimental Alzheimer's drug aims to lower brain 'Tangles' in Early-Stage patients
Disease control OngoingThis early-stage trial tests a drug called NIO752 in 38 people with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The drug is given as one or two injections into the spinal fluid to see if it can lower levels of tau protein, a key marker of Alzheimer's damage.…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a new drug slow Alzheimer's? large trial underway
Disease control OngoingThis phase 3 study tests whether donanemab, an antibody given through an IV, can safely slow cognitive decline in 1500 people with early Alzheimer's. Participants receive either the drug or a placebo for up to 93 weeks. The main goal is to measure changes in thinking and daily fu…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for Alzheimer's psychosis: Long-Term drug trial underway
Symptom relief By invitation onlyThis study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug …
Phase 2 • Sponsor: MapLight Therapeutics • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Alzheimer's imaging showdown: which tracer is better?
Knowledge-focused OngoingThis study compares two different radioactive tracers used in PET scans to measure tau tangles in the brain, a hallmark of Alzheimer's disease. Researchers will scan over 800 participants with either Flortaucipir or MK-6240 to see how well they work over time. The goal is to harm…
Phase 1 • Sponsor: Tharick Pascoal • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Brain scans reveal diabetes link to cognitive decline in rare disease
Knowledge-focused OngoingThis study looks at whether diabetes or blood sugar problems can worsen thinking and memory issues in people with myotonic dystrophy type 1. Researchers will use MRI brain scans and thinking tests over 4 years to track changes. The goal is to understand why some patients have mor…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC